Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory ....Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.Read moreRead less
Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis. The purpose of this study is to identify novel biomarkers in the tears of patients with CaP. The use of the several techniques will increase the chance of success and enable us to find more diagnostic markers. If successful, the identified proteins may be used to diagnose and determine the stage of cancer. This will help guide clinicians in choosing the best treatment methods for an individual patient. The m ....Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis. The purpose of this study is to identify novel biomarkers in the tears of patients with CaP. The use of the several techniques will increase the chance of success and enable us to find more diagnostic markers. If successful, the identified proteins may be used to diagnose and determine the stage of cancer. This will help guide clinicians in choosing the best treatment methods for an individual patient. The markers may also be used to monitor the disease progress and the effects of treatment. The results from this study may improve the prognosis of CaP patients.Read moreRead less
Development of a non-invasive diagnostic test of Embryo Viability. A successful outcome will:
. improve the cost effectiveness of assisted reproductive technologies resulting in reduced health care costs and allowing greater use of ART in animal production
. by greater cost-effectiveness, facilitate greater access to these advanced technologies in less well developed economies
. build the national capacity in development and validation of biotech diagnostics
. build collaborative relationsh ....Development of a non-invasive diagnostic test of Embryo Viability. A successful outcome will:
. improve the cost effectiveness of assisted reproductive technologies resulting in reduced health care costs and allowing greater use of ART in animal production
. by greater cost-effectiveness, facilitate greater access to these advanced technologies in less well developed economies
. build the national capacity in development and validation of biotech diagnostics
. build collaborative relationship between the CI, University of Sydney and a leading industry partner (Cook Australia)
. lead to significant new fundamental knowledge in embryology that will be of major International significance
Read moreRead less
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.
Targeting the undruggable: epitope mapping using Phylomers peptides to modulate activity of Transcription Factors. This project aims at expanding the pool of drug targets, by extending drug screening to protein-protein interaction networks. This project aims to assemble a novel technical platform to detect binding between proteins, using a combination of cell-free protein expression, AlphaScreen and single-molecule fluorescence. This pipeline has great potential to accelerate the exploration of ....Targeting the undruggable: epitope mapping using Phylomers peptides to modulate activity of Transcription Factors. This project aims at expanding the pool of drug targets, by extending drug screening to protein-protein interaction networks. This project aims to assemble a novel technical platform to detect binding between proteins, using a combination of cell-free protein expression, AlphaScreen and single-molecule fluorescence. This pipeline has great potential to accelerate the exploration of protein networks, and provides also a generic platform for drug screening on difficult targets. The project intends to screen Phylogica's libraries of peptides called Phylomers to discover tight binders to a Transcription Factor, Sox18. The objective of this project is to determine which Phylomers can disrupt specific interactions between Sox18 and its binding partners involved in lymphangiogenesis.Read moreRead less
A microfluidic array of phylomers for rapid discovery of peptide probes and biomarkers. This project, through an alliance with Phylogica, aims at exploiting a unique source of structural diversity for drug discovery, harvesting the creativity of nature in its most exotic places. The project will develop a novel approach to validate design and validate drug candidates, by gathering them on a single screening chip for a powerful discovery platform.
Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, ....Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, as an alternative to outdated chemical treatments. Expected outcomes include a unique scalable technology which will support Australia's sovereign capacity to produce high-value proteins, rapidly, affordably, and at scale, and with less complexity than current plant-based systems. Read moreRead less